Patients from 22+ countriesPlan your visit →
lutetium-therapy
Patient Journey · 19 Jul 2026

Erectile Dysfunction During Lu-177 PSMA Therapy

Erectile dysfunction is common in men receiving Lu-177 PSMA therapy for mCRPC - but the radioligand is rarely the direct cause. Understanding what drives ED during this treatment, and what options exist, can make a real difference to quality of life.

Editorial oversight by Arpan Talwar·Founder, Art of Healing CancerUpdated 19 Jul 2026
Erectile Dysfunction During Lu-177 PSMA Therapy

Erectile Dysfunction During Lu-177 PSMA Therapy

This article is for men on the PSMA track - specifically those with metastatic castration-resistant prostate cancer (mCRPC) who are receiving or considering lutetium Lu-177 vipivotide tetraxetan (brand name: Pluvicto). If you or someone you care for is dealing with erectile dysfunction (ED) during this treatment, you are not alone. ED is one of the most common and least-discussed challenges men face during advanced prostate cancer care - and there are realistic options worth knowing about.

Why So Many Men Have This Question

If your prostate cancer has progressed to mCRPC and you are on Lu-177 PSMA therapy, you are likely months or years into hormone treatments - and possibly prior chemotherapy as well. ED may have started before Lu-177 PSMA began, or it may have gotten noticeably worse since. Many men feel reluctant to raise it with their care team, or assume nothing can be done. Both assumptions are worth revisiting.

Sexual function matters as part of quality of life during cancer treatment. You do not need to accept significant ED as inevitable or permanent without first exploring your options with a specialist. Understanding why ED happens during this phase - and what is actually driving it - is the first step toward making informed decisions.

What Does Lu-177 PSMA Therapy Actually Do?

To understand why ED happens during this treatment period, it helps to know how Lu-177 PSMA therapy works. It targets a protein called PSMA (prostate-specific membrane antigen) on the surface of prostate cancer cells. A radioactive molecule - lutetium-177 - is attached to a targeting compound and given by infusion. It seeks out PSMA-positive cancer cells throughout the body and delivers focused radiation directly to them.

The VISION trial - the phase-3 study that supported FDA approval of lutetium Lu-177 vipivotide tetraxetan - documented the most common side effects as fatigue, nausea, dry mouth, decreased appetite, and low blood counts. Erectile dysfunction was not among the primary side effects directly linked to the radioligand in that data. That does not mean ED is rare in men on this therapy. It means the radioligand itself is not the primary cause. The picture is more layered - and understanding that is useful when thinking about solutions.

The Main Cause: Androgen Deprivation Therapy

Almost every man receiving Lu-177 PSMA therapy for mCRPC is also on some form of androgen deprivation therapy (ADT). ADT suppresses testosterone - the hormone that drives prostate cancer cell growth. But testosterone also plays a central role in sexual desire, the ability to get an erection, and overall sexual response.

When testosterone falls to castrate levels - as intended by ADT - the effects on sexual function are significant. Research reviewed in Advances in Urology shows that most men who are sexually active before starting continuous ADT experience loss of libido and erectile difficulties within the first few months of treatment. Loss of libido typically comes first. ED follows.

ADT is so central to managing advanced prostate cancer that conversations often focus on PSA control and disease management - and sexual function can fall off the agenda entirely. If your ED started or worsened after ADT began - and before Lu-177 PSMA was added to your regimen - this context matters. It may mean that addressing ADT-related causes is the most useful avenue to explore with your care team.

Other Factors That Can Contribute

ADT is usually the biggest driver, but several other factors can contribute to ED in men at this stage of prostate cancer. Knowing about them matters because they shape which management options are most likely to help your specific situation.

  • Prior local treatments. If you had surgery (radical prostatectomy) or pelvic radiation therapy earlier in your cancer journey, nerve or blood-vessel damage from those treatments may have already affected erectile function. Lu-177 PSMA delivers radiation to metastatic sites throughout the body and is less likely than pelvic radiotherapy to worsen this specifically - but the effects of prior local treatment are real and ongoing.
  • Cardiovascular and metabolic health. Healthy erections depend on good blood flow. High blood pressure, diabetes, and high cholesterol are common in older men and can contribute significantly to ED independently of cancer treatment. Men on ADT often gain weight and experience metabolic changes that can amplify these effects over time.
  • Other medications. Some drugs used during cancer care can affect sexual function as a secondary effect. A review of your full medication list with your oncologist or GP may be worthwhile if ED changed noticeably after a new medication was added.
  • Psychological factors. A diagnosis of mCRPC, uncertainty about treatment outcomes, fear, and relationship stress can all contribute to ED through their effect on mood, anxiety, and the nervous system. This is well-recognized, and it is worth addressing alongside any physical causes.
  • Fatigue. Significant fatigue during and after Lu-177 PSMA cycles is common and can reduce both libido and the physical energy available for sexual activity during active treatment periods.

What Can You Realistically Expect?

For men on continuous ADT - which describes most men with mCRPC - significant recovery of erectile function while ADT continues is unlikely. The low-testosterone environment that ADT creates is the main driver, and while that continues, its sexual effects will remain present.

That said, the picture is not identical for every man. Some retain some degree of erectile function on ADT, particularly in the earlier months of treatment. Others experience more rapid loss. Age, baseline health, prior treatments, and the specific ADT regimen all influence where you land on that spectrum. What can improve are surrounding factors - fatigue, psychological wellbeing, relationship communication, and cardiovascular health. Addressing these can meaningfully affect overall sexual quality of life, even when full erections are difficult.

Between Lu-177 PSMA cycles, some men find that fatigue eases during the later weeks of each cycle spacing period. This recovery window may be when energy and mood return enough to revisit intimacy with a partner. Noting when this happens relative to your treatment schedule can be useful information to share with your care team.

What Are Your Options for Managing ED?

Managing ED in men on ADT for advanced prostate cancer has moved well beyond simply accepting it. The Urology Care Foundation outlines several approaches used in clinical practice. Your specific situation - overall health, current medications, prior treatments, and personal priorities - will shape which are most appropriate for you.

Oral medications

PDE5 inhibitors (phosphodiesterase type 5 inhibitors) such as sildenafil and tadalafil work by increasing blood flow to the penis. They are often tried first because they are non-invasive and taken by mouth. In men on ADT, their effectiveness is lower than in men with ED from other causes - because low testosterone reduces their benefit - but some men still find value in them, especially at earlier stages of sexual function loss. A prescriber must review your overall health and other medications before recommending these.

Vacuum erection devices

A vacuum erection device (VED) is a cylinder placed over the penis with a pump that creates a gentle low-pressure vacuum, drawing blood into the penile tissue. A tension ring at the base of the penis holds the erection during use. VEDs require no medication and have no systemic effects, making them an option even when oral medications are not suitable. They take some practice to use comfortably, and some men use them not only for intercourse but to help maintain penile tissue health and blood flow during treatment.

Penile injections

Medications injected directly into the penile tissue - a process called intracavernous therapy - may produce an erection with a higher response rate than oral medications, including in men on ADT. The idea of self-injection can feel daunting at first, but many men become comfortable with it after instruction from a urology nurse or specialist. This approach requires a prescription and proper guidance before home use.

Penile implants

Surgically implanted penile prostheses are an established option for men who have tried other approaches without adequate success. This is generally considered after other options have been found insufficient, and it requires careful assessment of overall fitness for surgery and prognosis in discussion with both oncology and urology teams.

Psychological support and couples counselling

ED during cancer treatment is rarely purely physical. Anxiety, grief over changed body image, relationship strain, and depression all play a role. Psychosexual counselling - individually or with a partner - has solid evidence for improving quality of life, even when physical options are limited. Many oncology centres can refer you, or your GP can connect you with a specialist. Talk to your doctor before trying any supplements for sleep or stress.

Lifestyle changes

Cardiovascular health and erectile function are closely linked. Regular aerobic exercise, maintaining a healthy weight, and managing blood pressure and blood glucose may support erectile function by improving blood flow. Men on ADT often gain weight and lose muscle mass over time, both of which affect metabolic health. Exercise has been studied in prostate cancer patients on ADT and has shown benefit for quality of life and physical function. A physiotherapist or exercise specialist familiar with cancer rehabilitation can advise on what is safe for you during treatment.

Talking to Your Care Team

Many men do not raise ED with their oncologist because it feels off-topic, embarrassing, or less important than the cancer itself. Oncologists, in turn, are managing complex disease decisions and may not bring it up unless prompted. This gap is common - and worth closing. You can raise it simply: tell your doctor you are having difficulty with erections and would like to understand your options. That is enough to open the door. From there, your team may involve a urologist with specialist interest in sexual medicine, a pelvic health physiotherapist, a clinical psychologist, or a specialist nurse.

If you are still deciding whether Lu-177 PSMA is right for your situation - or you want an independent review before committing to a treatment centre - you can request a Lu-177 eligibility review through Art of Healing Cancer. The team there can give you a clear picture of where Lu-177 PSMA fits in your overall plan, and can advise on alternatives if it turns out not to be suitable for your case.

You can also send your PSMA-PET results and book a teleconsult directly via the Lutetium Therapy contact form. If Lu-177 PSMA is not the right next step, a second opinion on what alternatives exist is available through the same route.

After your treatment course, tracking how sexual function changes relative to treatment timing is useful clinical information. A well-structured follow-up plan after your Lu-177 PSMA cycles should include both disease response monitoring and side-effect monitoring - and sexual function belongs in that conversation, not separate from it.

When to Talk to Your Doctor

Raise sexual health concerns with your oncologist or care team if ED is significantly affecting your quality of life or your relationship. This is especially important if ED was not present before treatment began, if it has worsened noticeably since a new medication was added, or if you are also experiencing depression, significant anxiety, or difficulty sleeping. Your team can assess whether the cause is ADT-related, medication-related, or shaped by other factors - and connect you with the right specialist support.

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.

Frequently asked questions

Does Lu-177 PSMA therapy directly cause erectile dysfunction?

Lu-177 PSMA therapy (lutetium Lu-177 vipivotide tetraxetan) does not appear as a primary cause of erectile dysfunction in the main clinical trial data, including the VISION trial. The most commonly reported direct side effects of the radioligand are fatigue, nausea, dry mouth, and low blood counts. In most men receiving Lu-177 PSMA, the main driver of ED is the androgen deprivation therapy (ADT) they continue alongside treatment. Prior treatments such as surgery or pelvic radiation, and other health conditions, also play a role.

Will erectile function return after Lu-177 PSMA cycles end?

Whether erectile function returns depends mainly on whether ADT continues after the Lu-177 PSMA cycles are complete - not on the radioligand itself. Men who remain on long-term or continuous ADT are likely to continue experiencing ED from that cause. Men who had short-term ADT as part of their regimen may see some gradual recovery as testosterone slowly rises again over months after ADT is stopped. Discuss the expected duration of your ADT with your oncologist, as this is the key factor for sexual function recovery.

Can I take sildenafil or tadalafil during Lu-177 PSMA therapy?

PDE5 inhibitors such as sildenafil and tadalafil are not specifically contraindicated because of Lu-177 PSMA therapy, but they interact with some medications and are not suitable for men with certain heart or blood pressure conditions. In men on ADT, their effectiveness is reduced but some benefit may still be possible. Your oncologist or GP should review your full medication list before you start any new drug, including these.

Is it safe to have sex between Lu-177 PSMA cycles?

For most men, sexual activity is not medically restricted between cycles. However, in the days immediately following an infusion, standard radiation safety precautions apply - your treatment team will give you specific guidance, which typically includes limiting close prolonged contact and using barrier contraception for a defined short period. After that window passes, sexual activity is generally not restricted on medical grounds. Ask your nuclear medicine team for the specific timeframe they recommend based on your dose.

Should I tell my care team about ED even if it started before Lu-177 PSMA began?

Yes. ED that began earlier in your treatment - for example, after ADT started or following surgery or pelvic radiation - is still worth raising with your care team. It provides important baseline context and opens the door to management options that may have been available for some time but were never discussed. There is no wrong time to bring it up. Many oncology centres can connect you with a urologist or psychosexual specialist.

Are there supplements or natural remedies that help with ED during cancer treatment?

The evidence base for most supplements marketed for sexual function is limited, and the picture is even less clear in men on ADT for advanced prostate cancer. More importantly, some supplements can interact with cancer medications or affect how your body processes other drugs. Do not start any supplement for ED without first checking with your oncologist. What does have evidence in this context is regular aerobic exercise and good cardiovascular health management, both of which support blood flow and overall metabolic function.

Have a specific question about your situation?

A free conversation with a patient navigator can help you understand whether Lutetium therapy fits your case, what questions to ask your oncologist, and which centers might be right for you.

Navigators don't diagnose or prescribe. They help you have better conversations with the doctors who do.

ED and Lu-177 PSMA Therapy: Causes and Options | lutetium-therapy